Devonian Health Group, Inc. · TSXV:GSD
Devonian Health — Investor Presentation (August 2020)
29 slides from Devonian Health's investor presentation, August 2020
Slide 1: Corporate Presentation
Corporate Presentation TSXv: GSD August 2020 Farm toPharm™ 1
Slide 2: Cautionary Statements
Cautionary Statements Certain statements contained in this document constitute forward-looking information and forward-looking statements (collectively, “forward-looking statements”) pursuant to the Applicable Securities Regulations. All statements, other than statements of historical fact, containe
Slide 3: Devonian Health Group (TSXv-GSD) Farm to Pharm
Devonian Health Group (TSXv-GSD) Farm to PharmTM Overview Experienced Team ▪ Incorporated in 2015 and is headquartered in Québec, ▪ Management with solid track record of execution. Canada. ▪ A late stage Plant-Based Pharmaceutical company. LICENSED State-of-the-art extraction facility ▪ Core strateg
Slide 4: Prescription Plant-Based Drug Field and its Benefits
Prescription Plant-Based Drug Field and its Benefits Next Wave in Pharmaceuticals Benefits over Synthetic/Highly Purified Drug ▪ Specific FDA regulations ; Botanical Drug ▪ Faster preclinical development; Regulation ▪ Less costly; ▪ The FDA has already approved a number of plant- ▪ Up to 5 years mar
Slide 5: Botanical Drug Regulation: Approved Prescriptions
Botanical Drug Regulation : Approved Prescriptions PRODUCT INDICATION OWNER OF MARKETING AUTHORIZATION Veregen® 1 • Rx external genital and perianal warts Fougera Pharmaceuticals, a subsidiary of SANDOZ/NOVARTIS (US$200Bn market cap) Curasite™ 2 • Rx of Diabetic Foot Ulcers, Leg Ulcers etc. IZUN PHA
Slide 6: Strong Leadership and Advisory Groups
Strong Leadership and Advisory Groups Management Board of Directors André P. Boulet, PhD André P. Boulet, Ph.D. President & Chief Executive Officer Jacques Bernier, B.Pharm, MBA Nathalie Boucher, PhD Guy P. Dancosse, Q.C., Icd.D., Circ Director Research & Intellectual Property Sybil Dahan Sybil Daha
Slide 7: Devonian's 4-Pillar Strategy
Devonian’s 4-Pillar Strategy Focused Building Large Consortium Approach Commercial of Experts Proprietary Respecting FDA Unmet Technology and and Health Medical Licensed Canada Needs Production Plant Regulations 7 Farm toPharm™
Slide 8: TECHNOLOGY: Innovative and Patented Platform: SUPREX
TECHNOLOGY: Innovative and Patented Platform: SUPREX™ This process ensure traceability: genuine pharmaceutical approach SOURCING EXTRACTION DEVELOPMENT COMMERCIALIZATION Botanical Drug Active Complexes Non-synthesis (‘‘Entourage’’ effect of extracts) Chemical synthesis Traditional Pharmaceutical Che
Slide 9: LICENSED Pharmaceutical-grade (cGMP) production facility
LICENSED Pharmaceutical-grade (cGMP) production facility Pharmaceutical Grade Intellectual Property • Full scale facility with custom designed equipment ✓ Over 44 patents issued or pending • Pharmaceutical-grade production facility meeting ✓ 7 Trademarks Cleanroom Standards (ISO 14644-1) • Expect to
Slide 10: Sourcing Prescription Plant-Based Drugs
Sourcing Prescription Plant-Based Drugs Pharmaceutical Drug Company Sources Organic Plants Cannabis R-Spinasome® Cannabinoids : ThykamineTMC CBDs and Terpenes Inflammation Cosmeceuticals Anti Infective Dermatology 10 Farm toPharm™
Slide 11: Devonian's Target Therapeutic Areas and Indications
Devonian’s Target Therapeutic Areas and Indications World Market Choosing Lower Risk - Reward Initial Therapeutic Indications Forecasted by 2027 Initial indications chosen for their Ulcerative Colitis favorable development and (Inflammatory Bowel Disease) commercial profile Gastrointestinal botanica
Slide 12: Primary Focus: Thykamine: Potential First Line Therapy
Primary Focus: Thykamine™ : Potential First Line Therapy Strong drug candidate profile with potential to be “Best-In-Class” Potential 1st line therapy Non-chemical therapy in Ulcerative Colitis Lower costs Fewer adverse effects (Mabs, Antisense, etc.) Acceptance in As a Botanical Drug, difficult ped
Slide 13: Focus #1: Thykamine: a Novel Anti-Inflammatory Drug
Focus #1: Thykamine™: a Novel Anti-Inflammatory Drug Clinical Results (1) Clinical Symptoms (1) Rectal Bleeding – Modified Mayo Sub-Score 0 Patients with left- Placebo Day 7 Day 14 Day 21 -0.2 in Rectal Bleeding Sub-Score Mean Change from Baseline sided Mid-to- Moderate Ulcerative Colitis -0.4 (Flar
Slide 14: Focus #1: Thykamine, Day 21 - Outstanding Anti-Inflammatory effect
Focus #1: Thykamine™, Day 21 - Outstanding Anti-Inflammatory effect Biomarkers 60 40 20 0 % -20 -40 -60 Placebo Thykamine™ 250 mg/day -80 -100 (1) A 2-Week Exploratory Randomized, Double-Blind, Parallel- Group, Dose-Ranging, Placebo-Controlled Safety, Tolerability, Biomarker and Efficacy Clinical St
Slide 15: Focus #1: Thykamine, a Novel Anti-Inflammatory Drug
Focus #1: Thykamine™, a Novel Anti-Inflammatory Drug Demonstrated Benefits A Novel approach after 14 days of therapy in UC • Non-chemical therapy • Fast onset of action • Rx : expected 4 weeks / Once-a-day • Impact on symptoms • Fast onset of action • Decreased inflammatory and disease’s st • Potent
Slide 16: Focus #1: Thykamine - Atopic Dermatitis - Timeline
Focus #1: Thykamine™ - Atopic Dermatitis - Timeline November 2020 September 2021 June 2022 Agreement with large pharmaceutical Atopic Dermatitis Atopic Dermatitis • Fall 2020; initiate the search for a pharmaceutical (Eczema) (Eczema) partner • Adult – Phase 2 • Pediatric – Phase 2 • Target reaching
Slide 17: Focus #1: Thykamine - Ulcerative Colitis - Timeline
Focus #1: Thykamine™ - Ulcerative Colitis - Timeline March 2021 June 2022 June 2022 Agreement with large pharmaceutical • Fall 2020; initiate the search for a pharmaceutical Ulcerative Colitis Ulcerative Colitis partner • Phase 2b to be • Phase 2b clinical • Target reaching agreement: first half of
Slide 18: Focus #2: Pharmaceutical Cannabinoids Program
Focus #2: Pharmaceutical Cannabinoids Program Recreational Medical Pharmaceutical Gross Margins Low Low Hight >70% Limited by countries and regulated by Limited by countries and regulated by Commercialization Global government government Target Market Consumer Consumer Physicians Reimbursement (prov
Slide 19: Renewed Interest for Cannabinoids from Large Pharmaceuticals is Emerging
Renewed Interest for Cannabinoids from Large Pharmaceuticals is Emerging The pharmaceutical industry is under intense pressure to become more efficient and develop better, faster and cheaper drugs. Large Pharmaceutical companies Large Pharmaceutical Companies involved in clinical development Patents
Slide 20: Cannabinoids: Perfecting the Manufacturing Like no other
Cannabinoids: Perfecting the Manufacturing Like no other US FDA’s Approaches to Ensure the Therapeutic Devonian’s Approaches to Cannabinoids-Based Consistency of Botanical Drug Products 1 Botanical Drugs Well Controlled Well Controlled Botanical Raw Materials Botanical Raw Materials ➢ cGMP Cultivati
Slide 21: Devonian is building a Consortium of Experts in Cannabinoids-Based Pharmaceuticals
Devonian is building a Consortium of Experts in the Field of Cannabinoids-Based Pharmaceuticals • Positioning Devonian as the Canadian / World leader in the cannabinoid- based pharmaceutical drug development. • As per FDA’s Botanical Drug CannTx Cannabinoids-Based Pharmaceutical Extraction Regulatio
Slide 22: Large Commercial Opportunity: Therapeutic Potential of Cannabis-based RX
Large Commercial Opportunity Therapeutic Potential of Cannabis-based RX Cannabinoids have demonstrated beneficial effects across a number of indications, attracting interest in many diseases while leaving others underserved. Our Proposed Focus Anti- Significant Pain microbials Competition Underserve
Slide 23: Focus #2: Antimicrobial Drugs Based on Cannabinoids - Timeline
Focus #2: Antimicrobial Drugs Based on Cannabinoids - Timeline April 2021 January 2022 December 2022 Genetic Screening of Identification of flagship product(s) in the Agreement with large Cannabis Plants Humans, Veterinary and Food Industry pharmaceutical • Genetic screening of plants • Human and Ve
Slide 24: Focus #3: Development of Active Ingredients - Cosmeceutical market
Focus #3: Development of Active Ingredients - Cosmeceutical market Rationale - Research targeting cosmeceuticals (cosmetics with pharma-like clinical data) is intended to maximize the value of findings from its prescription drug research. Innovative Skin Care Backed Market Opportunity Exclusive Stra
Slide 25: Focus #3: Development of Active Ingredients - Cosmeceutical market
Focus #3: Development of Active Ingredients - Cosmeceutical market June 2021 Blue Light Protective Cream Marketing by our American • Clinical study results Distributor (SkinSciPac) Total Photoprotection Cream (SPF / Infra-red A / Blue Light) • Clinical study results 25 Farm toPharm™
Slide 26: Altius Healthcare - An Enabler to Devonian Strategy
Altius Healthcare - An Enabler to Devonian Strategy • In 2018, Devonian acquired Altius Healthcare Inc. • Altius’s business model is based on the acquisition or licensing of traditional pharmaceutical drugs developed by others. • Revenues from distribution of two pharmaceutical products, Cléo-35 and
Slide 27: Stock and Financial Information
Stock and Financial Information1 Capital Structure1 Shares Outstanding: Subordinate voting shares 62,556,017 Multiple voting shares (confers the right to 6 votes per share) 19,966,523 36% Total outstanding shares 82,522,540 Held by insiders Warrants 12,689,699 Stock Options 6,228,355 Fully diluted s
Slide 28: Investment Highlights and Value Accretive Milestones
Investment Highlights and Value Accretive Milestones Research and Development Potential Commercial Agreements September 2020 Pharmaceutical Cannabinoid Consortium Announcement • Under Cannabinoids-based pharmaceutical Consortium: November 2020 Adult Phase 2 Eczema topline results and patent submissi
Slide 29: THANK YOU
Research and Development Potential Commercial Agreements September 2020 Pharmaceutical Cannabinoid Consortium Announcement • Under Cannabinoids-based pharmaceutical Consortium: November 2020 Adult Phase 2 Eczema topline results and patent submission • July 2020 - Strategic alliance with Gayonica • J
Devonian Health Group — Investor Presentation (August 2020) on 6ix